The 24-week Phase 2 RECLAIM trial represents a major therapeutic shift in the development of Pemvidutide. Moving beyond its primary foundations in metabolic dysfunction-associated steatohepatitis (MASH) and obesity, these top-line data demonstrate how a balanced dual glucagon and GLP-1 receptor agonist can modulate central addictive neurocircuitry, significantly reducing heavy drinking days in patients with moderate-to-severe alcohol use disorder (AUD).
⚡ Quick Summary: Pemvidutide RECLAIM Trial Results
Quick Answer: In the 24-week Phase 2 RECLAIM trial evaluating approximately 100 adults with moderate-to-severe alcohol use disorder (AUD) and a BMI >25 kg/m², once-weekly pemvidutide demonstrated a statistically significant reduction in alcohol consumption compared to placebo. Pemvidutide reduced heavy drinking days per week by 4.20 days (versus 2.75 days with placebo). Furthermore, during the final month of evaluation (weeks 21–24), 42.2% of pemvidutide-treated patients reported zero heavy drinking days compared to 17.4% on placebo, establishing clinical proof-of-concept that dual incretin/glucagon peptides can modify addictive behavioral patterns while delivering hepatic metabolic protection.
| Evaluation Arm | Reduction in Heavy Drinking Days/Wk | Zero Heavy Drinking Days (Wks 21–24) | Primary Outcome Status |
|---|---|---|---|
| Pemvidutide (Weekly SubQ) | -4.20 days/week | 42.2% of cohort | Statistically superior vs. placebo |
| Placebo Control Arm | -2.75 days/week | 17.4% of cohort | Reflects structured behavioral trial support |
| Study Population Baseline | Moderate-to-Severe AUD + BMI >25 | Moderate-to-Severe AUD + BMI >25 | ~100 randomized participants (24 Weeks) |
| Treatment Discontinuation | 10.0% due to drug-related AEs | 0.0% on placebo | One possibly related case of hyponatremia |
What Is the Compound? Dual Glucagon and GLP-1 Pharmacology in Addiction
Pemvidutide is an investigational synthetic peptide engineered to activate both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) in an equimolar, balanced 1:1 ratio. Developed using a proprietary site-specific chemical platform, pemvidutide integrates a lipid moiety that extends its systemic half-life, supporting once-weekly subcutaneous dosing.
Historically, the clinical development of pemvidutide focused on non-alcoholic fatty liver disease (MASH) and chronic obesity. However, the neurobiological overlap between energy balance, gut-brain signaling, and substance use disorders led investigators to evaluate incretin-mediated behavioral modulation. Pemvidutide influences alcohol dependence through a coordinated central and peripheral axis:
- Mesolimbic Dopaminergic Attenuation (GLP-1R): GLP-1 receptors are densely expressed in the ventral tegmental area (VTA) and nucleus accumbens—the primary reward centers of the brain. Activation of central GLP-1 receptors dampens alcohol-induced dopamine surges, blunting the hedonic "reward" signal associated with ethanol consumption and reducing behavioral craving.
- Hepatic Metabolic Shielding (Glucagon Receptor): Heavy alcohol consumption drives severe hepatic steatosis, alcoholic hepatitis, and oxidative liver injury. While GLP-1 suppresses the behavioral drive to drink, glucagon receptor activation accelerates hepatic lipid beta-oxidation and clears intrahepatic fat. This dual action is uniquely suited to protect the liver from toxic ethanol metabolites while simultaneously lowering consumption.
This dual-target profile distinguishes pemvidutide from traditional addiction pharmacotherapies (such as naltrexone, acamprosate, or disulfiram), which target opioid or GABA/glutamate systems without addressing underlying metabolic liver injury or visceral adiposity.
How the Study Worked: RECLAIM Phase 2 Trial Architecture
The RECLAIM clinical trial was structured as a randomized, double-blind, placebo-controlled Phase 2 study designed to determine whether peptide-driven metabolic therapy could achieve clinically meaningful behavioral change in addiction medicine:
1. High-Risk Study Population
Randomized approximately 100 adults diagnosed with moderate-to-severe alcohol use disorder according to DSM-5 criteria, who concurrently presented with a BMI >25 kg/m², isolating a population with compounded metabolic and liver vulnerability.
2. 24-Week Treatment Window
Participants received once-weekly subcutaneous injections of pemvidutide or matching placebo over a 24-week period alongside standard, low-intensity behavioral counseling, assessing whether behavioral changes were durable over 6 months.
3. World Health Organization Risk Metrics
Tracked primary changes in heavy drinking days (defined as ≥5 standard drinks for men, ≥4 for women) and transitions across established WHO alcohol consumption risk tiers, evaluating harm reduction alongside abstinence.
4. Dual Liver & Metabolic Endpoints
Secondary endpoints rigorously monitored circulating hepatic biomarkers (ALT, AST, GGT) and changes in body weight, assessing whether reductions in ethanol intake produced parallel improvements in liver health.
Complete clinical protocol parameters and top-line announcements are documented in the Altimmune RECLAIM Primary Study Announcement.
Results and Key Findings: Robust Reduction in Ethanol Exposure
The 24-week top-line readout from RECLAIM confirms that dual incretin/glucagon receptor agonism significantly suppresses alcohol consumption in a population with active alcohol use disorder:
- Reduction in Heavy Drinking Days (-4.20 vs. -2.75): Patients receiving pemvidutide experienced an average reduction of 4.20 heavy drinking days per week from baseline, compared to a reduction of 2.75 days per week in the placebo cohort (a statistically significant between-group separation).
- Zero Heavy Drinking Days (42.2% vs. 17.4%): During the final month of the trial (weeks 21–24), 42.2% of pemvidutide-treated participants reported zero heavy drinking days, compared to just 17.4% in the placebo group.
- Harm Reduction vs. Absolute Abstinence: While achieving zero heavy drinking days represents a transformative clinical milestone, it should not be conflated with 100% complete abstinence from all alcohol. Many participants continued to consume low-to-moderate amounts of ethanol, shifting out of hazardous drinking tiers into low-risk categories.
- Contextualizing the Placebo Response: The substantial reduction observed in the placebo arm (-2.75 days/week) is an expected hallmark of addiction clinical trials, where daily drinking diaries, regular clinic visits, and structured investigator interaction provide therapeutic behavioral support. The critical finding is that pemvidutide provided robust, statistically superior benefit beyond this clinical trial effect.
The Study in Plain English: Understanding Addiction Trial Endpoints
Interpreting clinical trials in alcohol use disorder requires understanding the difference between total abstinence and validated clinical harm reduction:
| Trial Terminology | Clinical Addiction Definition | Real-World Patient Meaning |
|---|---|---|
| Heavy Drinking Day (HDD) | Consumption of ≥5 standard drinks for men, or ≥4 standard drinks for women in a single 24-hour period | Episodes of hazardous intoxication that drive alcohol-induced organ injury, blackouts, and accidents |
| Zero Heavy Drinking Days | No days exceeding the binge drinking threshold during a defined evaluation window | Elimination of dangerous drinking binges; patient consumes either zero alcohol or modest, low-risk amounts |
| WHO Drinking Risk Levels | Standardized tiers based on mean grams of pure ethanol consumed daily (Very High, High, Medium, Low) | Shifting from "Very High" to "Low" risk correlates with dramatic reductions in liver failure and mortality |
| Gut-Brain Mesolimbic Axis | Vagal and hypothalamic signaling connecting digestive satiety to central dopamine reward pathways | Blunts the subconscious "craving" reward loop triggered by sights, smells, or social cues for alcohol |
Key Insights: What Makes the RECLAIM Readout Groundbreaking?
The clinical contribution of RECLAIM extends beyond the borders of addiction psychiatry, opening a new chapter in peptide therapeutics:
- Proof of Incretin Efficacy in Substance Use: While retrospective real-world epidemiological databases had suggested that patients taking GLP-1 therapies reported reduced alcohol cravings, RECLAIM provides prospective, randomized, double-blind proof that a dual GLP-1/glucagon agonist suppresses heavy drinking behaviors.
- Treating the Dual Burden of Liver and Addiction: Chronic alcohol use disorder frequently coexists with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Pemvidutide addresses both problems simultaneously: dampening the neurological impulse to drink while actively mobilizing fat out of damaged hepatocytes.
- A Harm-Reduction Framework: Traditional addiction therapies often focus on strict abstinence, leading to high failure and dropout rates. By significantly expanding the proportion of patients achieving zero heavy drinking days, pemvidutide demonstrates that non-abstinent harm reduction is an achievable medical outcome.
Tolerability & The Complete Safety Profile
The safety and adverse-event spectrum documented in the RECLAIM study aligned with the known pharmacology of dual glucagon/GLP-1 co-agonists, while highlighting safety considerations specific to substance use populations:
- Gastrointestinal Adverse Events: Consistent with other incretin trials, mild-to-moderate nausea, vomiting, and diarrhea were the most common adverse effects, occurring predominantly during early dose titration.
- Discontinuation Rate (10.0% vs. 0.0%): Treatment discontinuations resulting from drug-related adverse events occurred in 10.0% of pemvidutide-treated patients, compared to 0.0% in the placebo group.
- Hyponatremia Signal: One serious adverse event (SAE) of hyponatremia (abnormally low blood sodium) was reported in the pemvidutide cohort and considered possibly treatment-related. This is a critical clinical finding: individuals with chronic alcohol use disorder are at baseline risk for electrolyte imbalances due to poor nutritional intake, beer potomania, and altered antidiuretic hormone secretion, indicating that electrolyte monitoring will be essential in future trials.
For complete trial documentation and primary corporate announcements, reference the Altimmune Primary Corporate News Release.
Synergistic Research Themes & Related Peptide Pathways
When examining pemvidutide's dual-action biology across metabolic, hepatic, and neurological systems, researchers explore complementary investigative models:
- Dual Incretin & Glucagon Biology: To contrast pemvidutide against other clinical dual-agonists targeting glucagon receptors, explore: Survodutide SYNCHRONIZE-1 Results: Phase 3 Obesity Trial Data.
- Mechanisms of Hepatic Reversal: Compare how incretin therapies reverse chronic liver scarring and fat accumulation in our analysis: Semaglutide ESSENCE Results: 72-Week Phase 3 MASH Trial.
- Systemic GLP-1 Pharmacology: Review the core receptor mechanisms, titration guidelines, and gastrointestinal considerations of incretin therapy: Semaglutide Explained: GLP-1 Receptor Action, Titration & Research.
What Patients and Clinicians Can Look Forward To
Pemvidutide remains an investigational drug that is not approved by the U.S. FDA or international health authorities for any clinical indication. However, following the successful completion of RECLAIM, Altimmune has announced plans to conduct formal end-of-Phase 2 regulatory discussions with the FDA and publish the full peer-reviewed dataset in a major medical journal.
If validated in larger, multi-center Phase 3 trials, pemvidutide could establish an entirely new class of medical therapies for alcohol use disorder. For clinicians, an agent that simultaneously reduces dangerous drinking binges, promotes weight loss, and reverses hepatic steatosis would address an urgent unmet need in addiction medicine and hepatology.
Questions for the Next Stage of Research
While the top-line RECLAIM findings provide encouraging proof-of-concept, several vital clinical questions guide ongoing investigation:
- Long-Term Durability & Post-Treatment Relapse: Will the reductions in heavy drinking days persist beyond 24 weeks, or will patients experience rebound cravings upon medication discontinuation?
- Verification with Objective Biomarkers: Will future Phase 3 programs confirm self-reported drinking diaries with objective biochemical markers of alcohol exposure, such as phosphatidylethanol (PEth) blood testing or urinary ethyl glucuronide (EtG)?
- Efficacy in Severe Alcoholic Hepatitis: Can the glucagon-mediated hepatic fat-clearing mechanism safely halt or reverse clinical decompensation in patients with advanced alcohol-associated liver disease (ALD) or cirrhosis?
Explore Our Research Tools
To assist laboratory scientists and clinicians in tracking peptide calculations, experimental schedules, and analytical observations, explore our specialized software suite:
- Calculate volume measurements and concentration parameters with the interactive Peptide Calculator.
- Structure research intervals, timing windows, and observation phases inside the Protocol Builder.
- Log laboratory markers, baseline patient metrics, and analytical notes with the Protocol Tracker Tool.
Scientific References & Primary Trial Documents
- Altimmune, Inc.: Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder (Primary News Release)
- Survodutide SYNCHRONIZE-1 Results: Phase 3 Obesity Trial Data
- Semaglutide Explained: GLP-1 Receptor Action, Titration & Research
Clinical Verdict: The Phase 2 RECLAIM clinical trial establishes that dual glucagon and GLP-1 receptor co-agonism via pemvidutide significantly reduces heavy drinking days and drives high rates of zero heavy drinking days in moderate-to-severe alcohol use disorder. By demonstrating that incretin/glucagon peptides can modulate central reward circuitry while concurrently providing metabolic and hepatic protection, pemvidutide opens a promising, evidence-based frontier in addiction therapeutics.
← View all clinical research, trials & peptide analyses in our Blog Archive
